Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-03-31
2011-11-08
Vivlemore, Tracy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500
Reexamination Certificate
active
08053420
ABSTRACT:
A therapeutic oligomer-peptide conjugate, and methods of using the conjugate are disclosed. The conjugate includes (a) a substantially uncharged oligonucleotide analog compound having a base sequence that includes a string of bases that are complementary to four or more contiguous cytosine bases in a target nucleic acid region to which the compound is intended to bind, and (b) conjugated to the compound, an arginine-rich peptide effective to enhance the uptake of the compound into target cells. The string of bases in the compound includes at least one inosine base positioned in the string so as to limit the number of contiguous guanine bases in said string to three or fewer. The conjugate has greater cellular uptake than the compound alone, by virtue of the arginine-rich peptide, and substantially greater antisense activity greater activity than the conjugate in the absence of inosine for guanine substitutions.
REFERENCES:
patent: 5087617 (1992-02-01), Smith
patent: 5525465 (1996-06-01), Haralambidis et al.
patent: 5747641 (1998-05-01), Frankel et al.
patent: 5849727 (1998-12-01), Porter et al.
patent: 6159946 (2000-12-01), Zalewski et al.
patent: 6303573 (2001-10-01), Ruoslahti et al.
patent: 6365351 (2002-04-01), Iversen
patent: 6495663 (2002-12-01), Rothbard et al.
patent: 6645974 (2003-11-01), Hutchinson et al.
patent: 7468418 (2008-12-01), Iversen et al.
patent: 2003/0032593 (2003-02-01), Wender et al.
patent: 2003/0040466 (2003-02-01), Vodyanoy et al.
patent: 2003/0045488 (2003-03-01), Brown et al.
patent: 2003/0087861 (2003-05-01), Iversen et al.
patent: 2003/0185788 (2003-10-01), Rothbard et al.
patent: 2003/0235845 (2003-12-01), Van Ommen et al.
patent: 2004/0170955 (2004-09-01), Arap et al.
patent: 2005/0171026 (2005-08-01), Hagiwara et al.
patent: 2006/0014712 (2006-01-01), Neuman
patent: 2006/0078542 (2006-04-01), Mah et al.
patent: 2006/0276425 (2006-12-01), Mourich et al.
patent: 2007/0135333 (2007-06-01), Geller et al.
patent: 2009/0082547 (2009-03-01), Iversen et al.
patent: 2009/0099066 (2009-04-01), Moulton et al.
patent: WO 94/04686 (1994-03-01), None
patent: WO 00/44897 (2000-08-01), None
patent: WO 00/71706 (2000-11-01), None
patent: WO 01/62297 (2001-08-01), None
patent: WO 03/068942 (2003-08-01), None
Abes et al., “Arginine-rich cell penetrating peptides: design, structure-activity, and applications to alter pre-mRNA splicing by steric-block oligonucleotides”,Journal of Peptide Science, 14:455-460 (2008).
Abes et al., “Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents”,Journal of Controlled Release, 116(3):304-13 (2006).
Arora et al., “Bioavailability and efficacy of antisense morpholino oligomers targeted to c-mycand cytochrome P-450 3A2 following oral administration in rats”,Journal of Pharmaceutical Sciences, 91(4):1009-1018 (2002).
Chen, C.P. et al., “A concise method for the preparation of peptide and arginine-rich peptide-conjugated antisense oligonucleotide”,Bioconjugate Chemistry, 14:532-538 (2003).
International Search Report from PCT Application No. PCT/US2004/013660, search report dated Feb. 21, 2005, 5 pages (2005).
Eriksson, M. et al.,“Cell permeabilization and uptake of antisense peptide-peptide nucleic acid (PNA) intoEscherichia coli”, The Journal of Biological Chemistry, 277(9):7144-7147 (2002).
Ghosh, C. and Iversen, P., “Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomers”,Antisense&Nucleic Acid Drug Development, 10:263-274 (2000).
Lebleu, B. et al., “Cell penetrating peptide conjugates of steric block oligonucleotides”,Advanced Drug Delivery Reviews, 60:517-529 (2008).
Marshall, N.B. et al., “Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing”,Journal of Immunological Methods, 325:114-126 (2007).
Moulton, H. et al., “HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers”,Antisense and Nucleic Acid Drug Development, 13(1):31-43 (2003).
Richard, J. P. et al., “Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake”,The Journal of Biological Chemistry, 278(1):585-590, 2003.
Rothbard, J. et al., “Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake”,J. Med. Chem. 45:3612-3618 (2002).
Stein et al., “Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers”,Antisense Nucleic Acid Drug Dev., 11(5):317-325 (2001).
Wender P. et al., “The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters”,Proc. Natl. Acad. Sci. USA, 97(24):13003-13008 (2000).
Wender, P. et al., “Oligocarbamate molecular transporters: design, synthesis, and biological evaluation of a new class of transporters for drug delivery”,J. Am. Chem. Soc.124:13382-13383, 2002.
Zubin, E. et al., “Oligonucleotide-peptide conjugates as potential antisense agents”,FEBS Letters, 456(1):59-62 (1999).
Dapic et al., “Biophysical and biological properties of quadruplex oligodeoxyribonucleotides”, 31(8):2097-2107 (2003).
Devi, G.R., “Prostate cancer: status of current treatments and emerging antisense-based therapies”,Current Opinion Therapies, 4(2):138-148 (2002).
Hudziak et al., “Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation”,Antisense Nucleic Acid Drug Dev., 6:267-272 (1996).
Iversen, P.L.,Antisense Drug Tech., S.T. Crooke, New York, Marcel Dekker, Inc. pp. 235-238 (2001).
Kang et al., “Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development”,Biochemistry, 37(18):6235-6239 (1998).
Knapp et al., “Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model.”,Anticancer Drugs, 14(1):39-47 (2003).
Mizutani et al.,Cancer, 74:2546-2554 (1994).
Moulton et al., “Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides”,Bioconjugate Chemistry, 15:290-299 (2004).
Shafer and Smirnov,Biopolymers, “Biological aspects of DNA/RNA quadruplexes”, 56(3):209-27 (2000).
Stein et al., “Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers”,Antisense Nucleic Acid Drug Dev., 11(5):267-272 (1996).
Summerton, J. and Weller, D., “Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers”,Antisense Nucleic Acid Drug Dev., 7:187-195 (1997).
Vanin, E.F. and Ji, T.H., “Synthesis and application of cleavable photoactivable heterobifunctional reagents”,Biochemistry, 20(24):6754-6760 (1981).
Alter et al., “Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology”,Nature Medicine, 12(2):175-7 (2006).
Burrer et al., “Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models”,Journal of Virology, 81(11):5637-5648 (2007).
EMBL/GenBank/DDBJ database (Deshazer) May 26, 2007 Sequence CH899747. Retrieved from the Internet URL,:http://www.ebi.ac.uk/sgi-bin/emblfetch?style+html&id+CH899747> 196 pages (2007).
Gebski et al., “Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle”,Human Molecular Genetics, 12(15):1801-11 (2003).
Jearawiriyapaisarn, N. et al., “Sustained Dystrophin Expression Induced by Peptide-conjugated Morpholino Oligomers in the Muscles of mdx Mice.”,Mol. Therapy, 16(9):1624-1629 (2008).
Kolonin et al., “Synchronous selection of homing peptides for multiple tissues by in vivo phage display&#
Hassinger Jed N.
Iversen Patrick L.
Weller Dwight D.
AVI BioPharma Inc.
Seed IP Law Group PLLC
Vivlemore Tracy
LandOfFree
Peptide conjugated, inosine-substituted antisense oligomer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide conjugated, inosine-substituted antisense oligomer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide conjugated, inosine-substituted antisense oligomer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4307021